University of California Berkeley
seal E. O. Lawrence Berkeley National
Laboratory seal
The
Carcinogenic Potency Project

Ethylene thiourea (CAS 96-45-7)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
liv(B) thy liv(B) thy liv pit thy liv pit thy 8.13m,v 23.5m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. pit = pituitary gland. thy = thyroid gland. (B) = experimental results were reported only for both sexes together. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Ethylene thiourea: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

ETHYLENE THIOUREA (ETU) 96-45-7 2748 M f b6c eat 25m25 TR388 : 0 42.9mg 130.mg liv MXA 19.9mg \ P<.0005 c 12.7mg 38.1mg 4/50 44/50 (48/50) liv:hpa,hpc. MXB MXB 26.6mg \ P<.0005 14.5mg 96.7mg 14/50 47/50 (48/50) liv:hpa,hpc; pit:pda,pdc; thy:fca,fcc. C liv hpa 30.5mg \ P<.0005 c 19.1mg 59.9mg 2/50 33/50 (14/50) liv hpc 39.7mg * P<.0005 c 28.4mg 62.9mg 2/50 29/50 47/50 thy MXA 82.0mg / P<.0005 c 55.5mg 128.mg 0/50 2/50 38/50 thy:fca,fcc. thy fca 90.9mg / P<.0005 c 60.6mg 144.mg 0/50 2/50 35/50 pit pda 147.mg * P<.003 c 74.6mg 973.mg 10/50 19/50 26/50 pit MXA 155.mg * P<.005 c 76.7mg 1.57gm 11/50 19/50 26/50 pit:pda,pdc. thy fcc 546.mg * P<.0005 c 246.mg 1.69gm 0/50 0/50 8/50 TBA MXB 120.mg * P<.08 46.2mg n.s.s. 36/50 49/50 48/50 liv MXB 19.9mg \ P<.0005 12.7mg 38.1mg 4/50 44/50 (48/50) liv:hpa,hpc,nnd. lun MXB 641.mg \ P<.7 93.4mg n.s.s. 5/50 8/50 (0/50) lun:a/a,a/c. 2749 M f b6c orl 81w81 1141 0 88.8mg Innes;ntis,1968/1969 liv hpt evx noTD50 P<.0005 n.s.s. 20.7mg 0/16 18/18 lun ade evx 203.mg P<.05 61.1mg n.s.s. 0/16 3/18 tba mix evx noTD50 P<.0005 n.s.s. 20.7mg 0/16 18/18 2750 M m b6c eat 25m25 TR388 : 0 39.6mg 120.mg liv MXA 54.1mg * P<.0005 c 30.6mg 158.mg 20/50 32/50 46/50 liv:hpa,hpc. MXB MXB 54.1mg * P<.0005 30.6mg 159.mg 21/50 32/50 47/50 liv:hpa,hpc; pit:pda; thy:fca,fcc. C liv hpc 54.6mg / P<.0005 c 33.5mg 116.mg 13/50 19/50 45/50 thy MXA 97.1mg / P<.0005 c 60.7mg 172.mg 1/50 1/50 29/50 thy:fca,fcc. thy fca 112.mg / P<.0005 c 69.6mg 194.mg 0/50 1/50 26/50 pit pda 387.mg * P<.0005 c 173.mg 1.20gm 0/50 0/50 8/50 thy fcc 730.mg * P<.04 c 246.mg n.s.s. 1/50 0/50 5/50 MXA hem 840.mg * P<.03 284.mg n.s.s. 0/50 1/50 3/50 ear:hem; hea:hem; liv:hem. S TBA MXB 89.2mg * P<.03 38.6mg n.s.s. 35/50 40/50 47/50 liv MXB 54.1mg * P<.0005 30.6mg 158.mg 20/50 32/50 46/50 liv:hpa,hpc,nnd. lun MXB 532.mg * P<.3 156.mg n.s.s. 5/50 6/50 8/50 lun:a/a,a/c. 2751 M m b6c orl 82w82 1141 0 82.5mg Innes;ntis,1968/1969 liv hpt evx 16.9mg P<.0005 + 7.63mg 40.5mg 0/16 14/16 lun ade evx 545.mg P<.3 88.7mg n.s.s. 0/16 1/16 tba mix evx 16.9mg P<.0005 7.63mg 40.5mg 0/16 14/16 2752 M f b6a orl 81w81 1141 0 88.8mg liv hpt evx 44.7mg P<.0005 20.4mg 124.mg 0/17 9/16 lun ade evx no dre P=1. 178.mg n.s.s. 1/17 0/16 tba mix evx 29.3mg P<.0005 13.2mg 99.9mg 2/17 12/16 2753 M m b6a orl 81w81 1141 0 82.6mg liv hpt evx noTD50 P<.0005 n.s.s. 20.0mg 1/18 18/18 lun ade evx no dre P=1. 87.7mg n.s.s. 2/18 2/18 tba mix evx noTD50 P<.0005 n.s.s. 21.8mg 3/18 18/18 2754 R f f34 eat 25m25 TR388 : 0 4.15mg 12.5mg thy MXA 7.42mg / P<.0005 c 4.74mg 13.2mg 1/50 6/50 28/50 thy:fab,fca. thy MXA 7.42mg / P<.0005 c 4.64mg 14.2mg 3/50 7/50 30/50 thy:fab,fca,fcy,fdc. thy MXA 39.6mg / P<.02 c 15.9mg n.s.s. 2/50 1/50 8/50 thy:fcy,fdc. TBA MXB 24.6mg * P<.5 5.13mg n.s.s. 48/50 46/50 49/50 liv MXB no dre P=1. 82.4mg n.s.s. 0/50 1/50 0/50 liv:hpa,hpc,nnd. 2755 R m f34 eat 25m25 TR388 : 0 3.32mg 10.0mg thy MXA 3.16mg * P<.0005 c 2.08mg 5.23mg 1/50 12/50 37/50 thy:fab,fca,fcy,fdc. thy MXA 5.25mg * P<.0005 c 3.28mg 9.00mg 0/50 9/50 23/50 thy:fab,fca. thy MXA 5.50mg / P<.0005 c 3.29mg 10.4mg 1/50 3/50 26/50 thy:fcy,fdc. TBA MXB 17.8mg * P<.5 3.49mg n.s.s. 43/50 47/50 43/50 liv MXB 186.mg * P<.2 30.3mg n.s.s. 0/50 0/50 1/50 liv:hpa,hpc,nnd. 2756 R b cdr eat 24m24 139 0 .225mg 1.13mg 5.63mg 11.3mg 22.5mg Graham;fctx,13,493-499;1975 --- fbs e 13.2mg Z P<.003 5.00mg 75.7mg 0/72 0/75 5/73 (4/73 5/69 3/70) thy mix e 16.6mg Z P<.0005 + 12.5mg 22.9mg 2/72 2/75 1/73 2/73 16/69 62/70 thy ade e 33.9mg Z P<.0005 + 20.0mg 70.6mg 2/72 0/75 5/73 1/73 21/69 (3/70) liv hpt e 330.mg * P<.04 + 117.mg n.s.s. 1/72 1/75 1/73 2/73 1/69 5/70 mgl adc e no dre P=1. 100.mg n.s.s. 2/72 14/75 4/73 2/73 5/69 (0/70) tba mix e 7.23mg * P<.0005 4.58mg 13.5mg 51/72 49/75 45/73 54/73 61/69 68/70 tba mal e 13.4mg Z P<.0005 9.62mg 19.9mg 15/72 23/75 13/73 16/73 31/69 63/70 2757 R f cdr eat 18m24 141m 0 6.56mg 13.1mg Ulland;jnci,49,583-584;1972/Weisburger 1981 thy fcc j 39.8mg * P<.03 + 18.0mg n.s.s. 0/10 2/26 6/26 thy ppc j 113.mg * P<.3 + 34.2mg n.s.s. 0/10 1/26 2/26 liv hnd j no dre P=1. 59.4mg n.s.s. 0/10 1/26 0/26 2758 R m cdr eat 18m24 141m 0 5.25mg 10.5mg thy fcc j 12.8mg / P<.0005 + 7.21mg 28.7mg 0/10 2/26 15/26 thy ppc j 90.5mg * P<.3 + 27.4mg n.s.s. 0/10 1/26 2/26 liv hnd j 179.mg * P<.8 27.7mg n.s.s. 0/10 2/26 1/26

Mutagenicity in Salmonella: positive
SMILES Code for Ethylene thiourea: S=C1NCCN1
InChI Code for Ethylene thiourea: InChI=1/C3H6N2S/c6-3-4-1-2-5-3/h1-2H2,(H2,4,5,6)
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Ethylene thiourea: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10